- Home
- MLYS
as of 12-05-2025 3:59pm EST
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | RADNOR |
| Market Cap: | 3.1B | IPO Year: | 2023 |
| Target Price: | $46.40 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.24 - $47.65 | Next Earning Date: | 11-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered MLYS Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Mineralys Therapeutics Inc. (MLYS)
Director
Avg Cost/Share
$46.08
Shares
15,000
Total Value
$689,797.08
Owned After
4,885
Director
Avg Cost/Share
$46.50
Shares
12,742
Total Value
$592,503.00
Owned After
0
SEC Form 4
Director
Avg Cost/Share
$46.89
Shares
6,933
Total Value
$323,885.67
Owned After
0
Chief Executive Officer
Avg Cost/Share
$44.23
Shares
200,000
Total Value
$9,088,498.87
Owned After
809,637
CFO and Secretary
Avg Cost/Share
$43.56
Shares
119,524
Total Value
$5,363,715.88
Owned After
52,114
Director
Avg Cost/Share
$44.76
Shares
15,000
Total Value
$659,706.00
Owned After
0
Chief Medical Officer
Avg Cost/Share
$43.01
Shares
10,369
Total Value
$445,982.10
Owned After
71,155
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$42.83
Shares
15,100
Total Value
$644,326.87
Owned After
809,637
CFO and Secretary
Avg Cost/Share
$42.08
Shares
10,758
Total Value
$451,983.56
Owned After
52,114
Chief Medical Officer
Avg Cost/Share
$36.19
Shares
11,367
Total Value
$409,265.98
Owned After
71,155
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Karydas Daphne | MLYS | Director | Nov 13, 2025 | Sell | $46.08 | 15,000 | $689,797.08 | 4,885 | |
| Gold Alexander M | MLYS | Director | Nov 13, 2025 | Sell | $46.50 | 12,742 | $592,503.00 | 0 | |
| Gold Alexander M | MLYS | Director | Nov 12, 2025 | Sell | $46.89 | 6,933 | $323,885.67 | 0 | |
| Congleton Jon | MLYS | Chief Executive Officer | Nov 11, 2025 | Sell | $44.23 | 200,000 | $9,088,498.87 | 809,637 | |
| Levy Adam Scott | MLYS | CFO and Secretary | Nov 11, 2025 | Sell | $43.56 | 119,524 | $5,363,715.88 | 52,114 | |
| Gold Alexander M | MLYS | Director | Nov 11, 2025 | Sell | $44.76 | 15,000 | $659,706.00 | 0 | |
| Rodman David Malcom | MLYS | Chief Medical Officer | Oct 15, 2025 | Sell | $43.01 | 10,369 | $445,982.10 | 71,155 | |
| Congleton Jon | MLYS | Chief Executive Officer | Oct 13, 2025 | Sell | $42.83 | 15,100 | $644,326.87 | 809,637 | |
| Levy Adam Scott | MLYS | CFO and Secretary | Oct 13, 2025 | Sell | $42.08 | 10,758 | $451,983.56 | 52,114 | |
| Rodman David Malcom | MLYS | Chief Medical Officer | Sep 15, 2025 | Sell | $36.19 | 11,367 | $409,265.98 | 71,155 |
Compare MLYS vs Leading Stocks
See how MLYS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MLYS Mineralys Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.